GlassScriptPhysician profile
Stanley Rosenberg
NPI 1982797999
$1,121.86
in general payments reported to CMS, 2019-2025
17 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $86.11 · 2021: $125 · 2022: $289 · 2023: $97.56 · 2024: $137 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $353.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $153.02 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $143.11 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $108.93 | 2021-2024 | Tecnis Iol, Tecnis Iol |
| Oyster Point Pharma, INC. | $106.54 | 2022-2024 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $104.91 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $93.74 | 2019 | |
| Novartis Pharmaceuticals Corporation | $78.38 | 2022-2023 | |
| Bausch & Lomb Americas INC. | $73.73 | 2024-2025 | Miebo, Scoutpro Osmolarity System |
| Alcon Vision LLC | $56.05 | 2024-2025 | Tryptyr, Simbrinza |
| Aerie Pharmaceuticals, INC. | $40.76 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $30.86 | 2024 | Xdemvy |
| Thea Pharma INC. | $23.99 | 2023 | Iyuzeh |
| Shire North American Group INC | $23.12 | 2019 | |
| New World Medical,INC. | $23.09 | 2024-2025 | Ahmed Glaucoma Valve, Clearpath, Kahook Dual Blade |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $22.92 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $21.29 | 2025 | Dextenza |
| Abbvie INC. | $17.42 | 2023 | Durysta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.